一种在质子笔束扫描FLASH放疗中最大化危及器官超高剂量率覆盖而不影响剂量学指标的新型剂量率优化方法
本研究开发了基于遗传算法的斑点序列优化框架,用于质子笔束扫描FLASH放疗中提高危及器官的超高剂量率覆盖。体模研究中核心危及器官轮廓的V40GyRBE/s从0%提高至约60%;10例肺癌患者中肺-GTV、脊髓、食管和心脏的V40GyRBE/s经序列优化后均显著提高(均P<.001)。
要点
- 遗传算法优化斑点递送序列可提高质子PBS FLASH放疗中危及器官的超高剂量率覆盖。
- 在65 nA束流下,肺癌患者肺-GTV、脊髓、食管和心脏的V40GyRBE/s优化后均显著提高(均P<.001)。
- 束流增至130 nA时V40GyRBE/s进一步提高(P<.05),布拉格峰FLASH技术在340 nA下各结构V40GyRBE/s亦增加。
核心结论
- 斑点递送序列优化作为计划优化后的独立过程,可保持最优计划质量。
- 体模和患者结果均表明,新型斑点递送序列优化可有效提高关键危及器官的超高剂量率覆盖,可能潜在应用于临床实践以改善危及器官保护效果。
研究设计与样本
- 本研究为剂量率优化框架研究,开发了基于斑点扫描模式的剂量率优化框架,并在院内治疗平台中实施遗传算法进行斑点序列优化。
- 进行了体模研究评估剂量率优化效果,并对10例既往接受质子笔束扫描调强质子治疗的肺癌患者连续计划进行优化验证,采用45 GyRBE分3次照射的透射式和布拉格峰FLASH放疗。
- 使用超高剂量率-体积直方图和剂量率覆盖率V40GyRBE/s定量评估剂量率优化效果。
主要发现
- 体模研究中,在相对较低的150 MU/spot(对应65 nA喷嘴束流)下,核心危及器官轮廓的FLASH剂量率比V40GyRBE/s从0%提高至约60%。
- 肺癌患者中,递送序列优化后肺-GTV、脊髓、食管和心脏的V40GyRBE/s分别从15.2%、15.5%、17.6%、16.0%提高至31.8%、43.5%、47.6%、30.5%(均P<.001)。
- 束流增至130 nA时,上述结构的V40GyRBE/s分别从45.1%、47.1%、51.2%、51.4%提高至65.3%、83.5%、88.1%、69.4%(P<.05)。
- 在65 nA和130 nA下,靶区和危及器官的平均V40GyRBE/s分别从12.9%提高至41.6%和从46.3%提高至77.5%。
- 布拉格峰FLASH技术在340 nA束流下优化剂量率后,肺GTV、脊髓、食管和心脏的V40GyRBE/s分别增加8.9%、15.8%、22%和20.8%。
临床怎么用
- 原文结论指出,斑点递送序列优化可有效提高关键危及器官的超高剂量率覆盖,可能潜在应用于临床实践以改善危及器官保护效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to investigate a dose rate optimization framework based on the spot-scanning patterns to improve ultrahigh-dose-rate coverage of critical organs at risk (OARs) for proton pencil beam scanning (PBS) FLASH radiation therapy (ultrahigh dose-rate (often referred to as >40 Gy per second) delivery) and present implementation of a genetic algorithm (GA) method for spot sequence optimization to achieve PBS FLASH dose rate optimization under relatively low nozzle beam currents. METHODS AND MATERIALS: First, a multifield FLASH plan was developed to meet all the dosimetric goals and optimal FLASH dose rate coverage by considering the deliverable minimum monitor unit constraint. Then, a GA method was implemented into the in-house treatment platform to maximize the dose rate by exploring the best spot delivery sequence. A phantom study was performed to evaluate the effectiveness of the dose rate optimization. Then, 10 consecutive plans for patients with lung cancer previously treated using PBS intensity-modulated proton therapy were optimized using 45 GyRBE in 3 fractions for both transmission and Bragg peak FLASH radiation therapy for further validation. The spot delivery sequence of each treatment field was optimized using this GA. The ultrahigh-dose-rate-volume histogram and dose rate coverage V40GyRBE/s were investigated to assess the efficacy of dose rate optimization quantitatively. RESULTS: Using a relatively low monitor unit/spot of 150, corresponding to a nozzle beam current of 65 nA, the FLASH dose rate ratio V40GyRBE/s of the OAR contour of the core was increased from 0% to ∼60% in the phantom study. In the patients with lung cancer, the ultrahigh-dose-rate coverage V40GyRBE/s was improved from 15.2%, 15.5%, 17.6%, and 16.0% before the delivery sequence optimization to 31.8%, 43.5%, 47.6%, and 30.5% after delivery sequence optimization in the lungs-GTV (gross tumor volume), spinal cord, esophagus, and heart (for all, P < .001). When the beam current increased to 130 nA, V40GyRBE/s was improved from 45.1%, 47.1%, 51.2%, and 51.4% to 65.3%, 83.5%, 88.1%, and 69.4% (P < .05). The averaged V40GyRBE/s for the target and OARs increased from 12.9% to 41.6% and 46.3% to 77.5% for 65 and 130 nA, respectively, showing significant improvements based on a clinical proton system. After optimizing the dose rate for the Bragg peak FLASH technique with a beam current of 340 nA, the V40GyRBE/s values for the lung GTV, spinal cord, esophagus, and heart were increased by 8.9%, 15.8%, 22%, and 20.8%, respectively. CONCLUSIONS: An optimal plan quality can be maintained as the spot delivery sequence optimization is a separate independent process after the plan optimization. Both the phantom and patient results demonstrated that novel spot delivery sequence optimization can effectively improve the ultrahigh-dose-rate coverage for critical OARs, which can potentially be applied in clinical practice for better OARs-sparing efficacy.
引用
- Zhao X, Huang S, Lin H, et al. A Novel Dose Rate Optimization Method to Maximize Ultrahigh-Dose-Rate Coverage of Critical Organs at Risk Without Compromising Dosimetry Metrics in Proton Pencil Beam Scanning FLASH Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024. PMID: 38879087. doi:10.1016/j.ijrobp.2024.06.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。